Publicacións en colaboración con investigadores/as de University of Florence (5)

2021

  1. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7

2020

  1. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 396, Núm. 10253, pp. 759-769

2019

  1. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue

    Pharmacological Research, Vol. 144, pp. 51-65

2016

  1. European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology

    European Heart Journal, Vol. 37, Núm. 2, pp. 164-173

2006

  1. No direct effect of creatine phosphate on the cross-bridge cycle in cardiac myofibrils

    Pflugers Archiv European Journal of Physiology, Vol. 452, Núm. 1, pp. 3-6